Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Cough - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Chronic cough - Pipeline Review, H2 2015', provides an overview of the Chronic cough's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic cough and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic cough - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic cough and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic cough pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic cough - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic cough pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chronic Cough Overview 6 Therapeutics Development 7 Pipeline Products for Chronic Cough - Overview 7 Chronic Cough - Therapeutics under Development by Companies 8 Chronic Cough - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Chronic Cough - Products under Development by Companies 11 Chronic Cough - Companies Involved in Therapeutics Development 12 Afferent Pharmaceuticals, Inc. 12 Ario Pharma Ltd 13 AstraZeneca Plc 14 Conrig Pharma ApS 15 Glenmark Pharmaceuticals Ltd. 16 Patara Pharma, Inc. 17 Chronic Cough - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 26 AF-219 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 cromolyn sodium - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 GRC-17536 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 lesogaberan - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ST-015 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 XEND-0501 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Chronic Cough - Recent Pipeline Updates 34 Chronic Cough - Dormant Projects 37 Chronic Cough - Discontinued Products 38 Chronic Cough - Product Development Milestones 39 Featured News & Press Releases 39 Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 39 Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 40 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Chronic Cough, H2 2015 7 Number of Products under Development by Companies, H2 2015 8 Comparative Analysis by Clinical Stage Development, H2 2015 9 Comparative Analysis by Early Stage Development, H2 2015 10 Products under Development by Companies, H2 2015 11 Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 12 Chronic Cough - Pipeline by Ario Pharma Ltd, H2 2015 13 Chronic Cough - Pipeline by AstraZeneca Plc, H2 2015 14 Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2015 15 Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 16 Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2015 17 Assessment by Monotherapy Products, H2 2015 18 Number of Products by Stage and Target, H2 2015 20 Number of Products by Stage and Mechanism of Action, H2 2015 22 Number of Products by Stage and Route of Administration, H2 2015 24 Number of Products by Stage and Molecule Type, H2 2015 25 Chronic Cough Therapeutics - Recent Pipeline Updates, H2 2015 34 Chronic Cough - Dormant Projects, H2 2015 37 Chronic Cough - Discontinued Products, H2 2015 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.